FDA Expands Mounjaro Use for Cardiovascular Risk Reduction in Type 2 Diabetes

The FDA has expanded the approval for Eli Lilly's Mounjaro (tirzepatide) to include reducing the risk of major cardiovascular events, such as heart attack and stroke, in adults with high-risk type 2 diabetes. This decision broadens the drug's therapeutic scope beyond blood sugar control, highlighting its significant benefits for heart health in this patient population.